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Abstract
Background: Rotenone inhibits the electron transfer from complex I to ubiquinone, in this way interfering with the
electron transport chain in mitochondria. This chain of events induces increased levels of intracellular reactive
oxygen species, which in turn can contribute to acceleration of telomere shortening and induction of DNA
damage, ultimately resulting in aging. In this study, we investigated the effect of rotenone treatment in human
fibroblast strains.
Results: For the first time we here describe that rotenone treatment induced a hormetic effect in human
fibroblast strains. We identified a number of genes which were commonly differentially regulated due to low
dose rotenone treatment in fibroblasts independent of their cell origin. However, these genes were not among
the most strongly differentially regulated genes in the fibroblast strains on treatment with rotenone. Thus, if there
is a common hormesis regulation, it is superimposed by cell strain specific individual responses. We found the
rotenone induced differential regulation of pathways common between the two fibroblast strains, being weaker
than the pathways individually regulated in the single fibroblast cell strains. Furthermore, within the common
pathways different genes were responsible for this different regulation. Thus, rotenone induced hormesis was
related to a weak pathway signal, superimposed by a stronger individual cellular response, a situation as found
for the differentially expressed genes.
Conclusion: We found that the concept of hormesis also applies to in vitro aging of primary human fibroblasts.
However, in depth analysis of the genes as well as the pathways differentially regulated due to rotenone
treatment revealed cellular hormesis being related to weak signals which are superimposed by stronger
individual cell-internal responses. This would explain that in general hormesis is a small effect. Our data indicate
that the observed hormetic phenotype does not result from a specific strong well-defined gene or pathway
regulation but from weak common cellular processes induced by low levels of reactive oxygen species. This
conclusion also holds when comparing our results with those obtained for C. elegans in which the same low
dose rotenone level induced a life span extending, thus hormetic effect.
Introduction
Oxidative stress is defined as an excessive load of Reactive
Oxygen Species (ROS) which cause reversible or persist-
ent damage on a cellular or systemic level. However, oxi-
dative stress is dose dependent [1]: high oxygen levels can
cause severe damage while low levels of ROS can be bene-
ficial to the organism, resulting in an extended life span
[2, 3]. Such biphasic responses to a potentially harmful
compound are commonly named hormesis, a concept that
was initially postulated by [4] and which was shown to
have significant impact on aging with a variety of stressors
described [3, 5–10]. Adaptive response processes may ex-
plain how increased ROS formation culminates in the
promotion of life span [2, 11, 12]. Yet, it is not fully eluci-
dated however, which molecular sensors become directly
activated by ROS. In yeast, inhibition of Target of Rapa-
mycin (TOR) extends chronological life span by increasing
mitochondrial ROS (mROS) [13]. In C. elegans, glucose
restriction increases mROS to increase life span [14, 15].
A redox-dependent hormetic response can also regulate
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the life span of Drosophila [16] and a correlation between
increased mROS and prolonged life span was observed in
mice [17]. These data can be explained by the hypothesis
that a mild increase of ROS and other stressors might lead
to a secondary increase in stress defense, culminating in
reduced net stress levels and possibly extended life span
[14, 18–24]. Currently however, we cannot exclude alter-
native hypotheses explaining low level ROS induced
hormesis. Low mROS levels might also extend life span in
humans. In vivo data regarding regulation of life span of
humans are scarce. Instead, replicative senescence of hu-
man cells in vitro has been studied as a surrogate for the
human life span. In cellular senescence, cells, though
metabolically active, stop dividing after a finite number of
cell divisions (called the “Hayflick limit”) [25]. Cellular
senescence contributes to aging via accumulation of sen-
escent cells in various tissues and organs during life; sen-
escent cells have been hypothesized to disrupt tissue
structure and function due to the components they se-
crete. In primates, the percentage of senescent skin fibro-
blasts increases with age in vivo [26] while senescent cell
deletion delays aging-associated disorders in mice [27].
Senescent cells contribute to the decline in tissue integrity
and function, rendering the human body susceptible to a
number of age-related diseases [28, 29]. These results indi-
cate that cellular senescence is causally implicated in
generating age-related phenotypes and that removal of
senescent cells can prevent or delay tissue dysfunction
and extend health span, linking cellular to tissue and or-
ganismal aging. Cellular senescence can be induced by
several mechanisms, in most cases involving oxidative or
oncogenic stress [30]. Human diploid fibroblasts display
an increase in replicative life span under hypoxia [31].
Hypoxia increases cellular ROS levels which were found
to be required for the increase of the replicative life span
of human fibroblast cells [32]. However, a brief exposure
to hyperbaric oxygen or juglone (a compound that gen-
erates ROS) can increase life span in C. elegans [33].
Rotenone interferes with the electron transport chain
in mitochondria, producing increased levels of intracel-
lular ROS due to inhibition of electron transfer from
complex I to ubiquinone [34, 35]. Therefore, rotenone
can be applied to mimic a physiological increase of
ROS as a trigger for cellular aging [36]. Rotenone is a
color- and odorless chemical with a broad spectrum of
use as an insecticide [37], pesticide [38] and piscicide
[39]. Rotenone has been extensively used in age related
studies revealing cell line and experimental model spe-
cific responses [35, 36, 40–46]. Rotenone induced ROS
increase can accelerate telomere shortening and can
cause DNA damage, followed by a robust DNA damage
response and senescence [47–50]. In addition to aging,
mitochondrial dysfunction can result in a number of
chronic conditions in humans, including Alzheimer’s
disease [51], diabetes [52] and obesity [53]. However, low
dose rotenone revealed a lifespan extending capability in
C. elegans [40].
In this study we investigated the effect of rotenone as a
stressor in primary human fibroblasts. We assessed the
transcriptomes of primary human fibroblast strains in the
presence and absence of mild doses of rotenone during
their transition into senescence. We studied the effects of
rotenone in MRC-5 fibroblasts derived from male embry-
onic lung [54], human foreskin fibroblasts (HFF) derived
from foreskin of 10 year old donors [55, 56] and WI-38
fibroblasts derived from female embryonic lung [57, 58].
Our data show that the concept of hormesis also applies
to in vitro aging of primary human fibroblasts.
Materials and methods
Cell strains
Primary human fibroblast cell strains were: MRC-5
(Homo sapiens, 14 weeks gestation male, from normal
lung, normal diploid karyotype, LGC Standards GmbH,
Wesel, Germany), WI-38 (Homo sapiens, 3 months gesta-
tion female, normal lung, normal diploid karyotype, LGC
Standards GmbH, Wesel, Germany) and HFF (human
foreskin fibroblast, Homo sapiens, normal diploid karyo-
type, a kind gift of T. Stamminger, University of Erlangen,
Germany [59]).
Cell culture
The fibroblast strains were cultured as recommended by
LGC in Dulbeccos modified Eagles low glucose medium
(DMEM) with L-glutamine (PAA Laboratories, Pasching,
Austria), supplemented with 10 % fetal bovine serum
(FBS) (PAA). The strains were grown under normal air
conditions in a 9.5 % CO2 atmosphere at 37 °C. The
fibroblasts were maintained separately in the presence of
different concentrations (0–2 μM) of rotenone (R8875;
Sigma-Aldrich, St. Louis, MO, USA) throughout their
span in culture in dim light, due to the light sensitive
nature of rotenone [41]. The media were changed and
rotenone was supplemented every 3 days to compensate
for its short half-life [60].
For sub-culturing, the remaining medium was dis-
carded and cells were washed in 1xPBS (pH 7.4) (PAA)
and detached using trypsin/EDTA (PAA). Primary fi-
broblasts were sub-cultured in a 1:4 (=2 population
doublings (PDs)) or 1:2 (=1 PD) ratio. For stock pur-
poses, strains at various PDs were cryo-conserved in
cryo-conserving medium (DMEM + 10 % FBS + 5 %
DMSO). Cells were immediately frozen at −80 °C and
stored for 2–3 days. Thereafter, cells were transferred
to liquid nitrogen for long time storage. No re-thawing
and re-freezing was done to avoid induction of prema-
ture senescence [61].
Marthandan et al. Immunity & Ageing  (2015) 12:11 Page 2 of 14
One vial of each of the 3 different fibroblast strains
(MRC-5, HFF and WI-38) were obtained and maintained
in culture from an early PD. On obtaining enough stock
on confluent growth of the fibroblasts in 75 cm2 flasks,
cells were sub-cultured into 3 different 75 cm2 flasks
(“triplicates”) and were maintained until they were sen-
escent in culture.
Detection of senescence associated β-galactosidase
(SA β-Gal)
The SA β-Gal assay was performed as described by [62]
in each of the 3 fibroblast strains with and without
rotenone. Cells were washed in 1xPBS (pH 7.4) and
fixed in 4 % paraformaldehyde (pH 7.4), 10 min at
room temperature (RT). After washing the cells in
1xPBS (pH 7.4), staining solution was added consisting
of 1 mg/ml X-Gal, 8 mM citric acid/sodium phosphate
pH 6.0, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 150 mM
NaCl, 2 mM MgCl2. The enzymatic reaction occurred
without CO2 for 4–16 h at 37 °C. After incubation, cells
were washed in 1xPBS (pH 7.4) and, in order to visualize
cell nuclei, DNA and Senescence Associated Heterochro-
matin Foci (SAHFs), mounted with 4′-6-diamidine-2-
phenyl indole (DAPI) containing Prolong Gold antifade
reagent (Invitrogen, Carlsbad, CA, USA). The total
number of cells and the number of SA β-Gal stained blue
cells were counted. Paired 2-sample type 2 Student’s t-
tests, assuming equal variances, were applied to examine
the statistical significance of the results obtained by the
SA β-Gal assay.
RNA extraction
Total RNA was isolated using Qiazol (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol, with
modifications. In brief, the fibroblasts were pelleted in
2 ml safe-lock tubes (Eppendorf, Hamburg, Germany).
1 ml cooled Qiazol and one 5 mm stainless steel bead
(Qiagen) were added. Homogenization was performed
using a TissueLyzer II (Qiagen) at 20 Hz for 1 min. After
incubation for 5 min at RT, 200 ml chloroform was added.
The tube was shaken for 15 s and incubated for 3 min at
RT. Phase separation was achieved by centrifugation at
12,000 g for 20 min at 4 °C. The aqueous phase was trans-
ferred into a fresh cup and 10 mg of glycogen (Invitrogen),
0.16 volume NaOAc (2 M, pH 4.0) and 1.1 volume isopro-
panol were added, mixed and incubated for 10 min at RT.
The RNA was precipitated by centrifugation with 12,000 g
at 4 °C for 20 min. The supernatant was removed and the
pellet was washed with 80 % ethanol twice and air dried
for 10 min. The RNA was re-suspended in 20 ml DEPC-
treated water by pipetting up and down, followed by incu-
bation at 65 °C for 5 min. The RNA was quantified with a
NanoDrop 1000 (PeqLab, Erlangen, Germany) and stored
at −80 °C until use.
High-throughput RNA sequencing
For quality check, total RNA was analyzed using Agilent
Bioanalyzer 2100 (Agilent Technologies, Santa Clara,
CA, USA) and RNA 6000 Nano Kit (Agilent) to ensure
appropriate RNA quality in terms of degradation. For
MRC-5 fibroblasts, the RNA integrity number (RIN)
varies between 7.9 and 9.6 with an average of around
8.7. Total RNA was used for Illumina library preparation
and next-generation sequencing [63]. Around 2.5 μg
total RNA was used for indexed library preparation
using Illumina’s TruSeq™ RNA Sample Prep Kit following
the manufacturer’s instruction. Libraries were quantified/
quality-checked using the Agilent 2100 and DNA 7500
Kit (both Agilent), pooled and sequenced (4 samples per
lane) using a HiSeq2000 (Illumina, San Diego, CA, USA)
in single-read mode (SR) with 50 cycles using sequencing
chemistry v2. Sequencing resulted in approximately 40
million reads with a length of 50 base pairs (bp) per sam-
ple. Reads were extracted in FastQ format using CASAVA
v1.8.2 (Illumina).
For HFFs, the RIN was roughly 10 for all samples.
Library preparation, quantification and quality checking
was done as described above, 1 μg total RNA was used
as input material. Sequencing was performed in pools
of 5 per lane on a HiSeq2500 in high-output mode
(50 bp SR, sequencing chemistry v3). Again around 40
million reads were obtained. For extraction of reads in
FastQ format, CASAVA v1.8.4 was used.
RNA-seq data analysis
Raw sequencing data were received in FASTQ format.
Read mapping was performed using Tophat 2.0.6 [64] and
the human genome references assembly GRCh37.66
(http://feb2012.archive.ensembl.org). The resulting SAM
alignment files were processed using featureCounts
v1.4.3-p1 [65] and the respective GTF gene annotation,
obtained from the Ensembl database [66]. Gene counts
were further processed using the R programming language
[67] and normalized to Reads per kilo base per million
mapped reads (RPKM) values. RPKM values were com-
puted using exon lengths provided by featureCounts and
the sum of all mapped reads per sample.
Sample clustering and analysis of variance
Spearman correlation between all samples was computed
in order to examine the variance and the relationship of
global gene expression across the samples, using genes
with raw counts larger than zero. Additionally, principal
component analysis (PCA) was applied using the log2
RPKM values for genes with raw counts larger than zero.
Detection of differential expression
The Bioconductor packages DESeq 1.10.4 [68] and edgeR
3.4.2 [69] were used to identify differentially expressed
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genes. Both packages provide statistics for determining
the differential expression in digital gene expression
data using a model based on the negative binomial
distribution. The non-normalized gene counts have
been used here, since both packages include internal
normalization procedures. The resulting p-values were
adjusted using the Benjamini and Hochberg’s approach
for controlling the false discovery rate (FDR) [70].
Genes with an adjusted p-value < 0.05, found by both
packages on rotenone treatment compared to controls,
were assigned as differentially expressed.
Gene set enrichment analysis to determine the most
differentially regulated pathways on aging
We used the R package gage [71] in order to find signifi-
cantly enriched (Kyoto Encyclopedia of Genes and
Genomes) KEGG pathways. In case of our RNA-seq data,
the calculation, based on the gene counts, was performed
as described in the methods manual (http://bioconductor.-
org/biocLite.R). For the public microarray based datasets,
the calculation was based on log2 fold-changes estimated
by limma (http://bioconductor.org/packages). Estimated
p-values were adjusted using the [70] approach for
controlling false discovery rates. KEGG pathways were
selected as significantly regulated if the FDR corrected p-
values were smaller than 0.05. We investigated the most
differentially regulated pathways at PDs showing a signifi-
cant delay in induction of senescence on rotenone treat-
ment, as detected by SA-β Gal.
Results
We investigated the effect of a low dose of rotenone as a
stressor in three different primary human fibroblast cell
strains: MRC-5 (male) and WI-38 (female) are from lung
tissue while HFFs (male) are skin derived. At several time
points in their life span under none or low dose rotenone,
we isolated total RNA and assessed the transcriptomes
and differentially expressed genes by high-throughput
RNA sequencing.
Impact of rotenone perturbation on induction of
senescence and replicative potential of primary human
fibroblast strains
In order to assess a low dose concentration, we added
rotenone to the culture medium of growing MRC-5 fibro-
blasts at various concentrations in the range 0 to 2 μM.
Applying rotenone concentrations higher than 0.1 μM
induced apoptosis in MRC-5 fibroblasts at different time
points during their span in culture (Additional file 1: Table
S1), consistent with observations in MCF-7 cells [42]. A
concentration of 0.1 μM rotenone was selected as ‘mild
stress’ condition since it did not cause any cell death over
extended periods of fibroblast passaging (Figs. 1a and 2a;
Additional file 2: Figure S1A). In young (PD 30) MRC-5
fibroblasts, 0.1 μM rotenone supplementation resulted in
a delay in induction of senescence as indicated by the
senescence marker SA β-Gal (Fig. 1b). A similar effect was
observed in foreskin fibroblasts (HFF) (Fig. 2b). However,
when treating young (PD 32) WI-38 fibroblasts with
0.1 μM rotenone, we detected no delay in senescence
induction and no change in the replicative potential
(Additional file 2: Figure S1A and B). Taken together, mild
oxidative stress treatment using rotenone did not have a
life span-extending effect but it induces a delay of senes-
cence, at least in MRC-5 and HFF fibroblasts.
In contrast to young MRC-5, treating older MRC-5
fibroblasts, beginning from the mid stage of their lifespan
(PD 50), with 0.1 μM rotenone did not delay senescence
induction, compared to DMSO treated controls (Fig. 1c).
Thus, low dose rotenone resulted in a delay in senescence
induction only when young MRC-5 cells were treated.
High-throughput RNA sequencing of low dose rotenone
treated fibroblasts
Total RNA was isolated from MRC-5 cells at four and
from HFF cells at six different time points during their
span in culture (Table 1). The samples were subjected to
high-throughput RNA sequencing (RNA-seq) [64, 65].
This approach enabled us to quantitatively measure
genome-wide polyA+ transcript levels and to determine
differentially expressed genes (DEGs) in rotenone treated
fibroblasts compared to controls. We found that rote-
none addition resulted in most DEGs at PDs 42 and 48
in MRC-5 and PDs 26, 30, 34 and 58 in HFFs (Table 1).
Analysis of variance and sample clustering
First, the normalized transcriptome expression values,
obtained from high-throughput RNA sequencing, were
analyzed using principal component analysis (PCA). PCA
reveals the internal structure of the data in a way that best
explains their variance. PCA identified the smallest
variances between biological replicates (“triplicates”, see
Materials & Methods; Fig. 3). PCA indicated a separation
of the MRC-5 and HFF cell strains (PC2) as well as the
difference between early and late PDs (PC1). The effect of
replicative senescence exhibited similarities between
MRC-5 and HFF since, for both cell strains, young and
old samples are located from the left to the right part in
Fig. 3. The strongest effects of the treatment with rote-
none, revealed by variances in gene expression, was de-
tected for PD 42 and 48 in MRC-5 and PD 30 and 58 in
HFF.
Rotenone treatment induced differentially expressed
genes (DEGs)
Next, we retrieved commonly differentially expressed
genes (DEGs) due to rotenone treatment in MRC-5 at
PDs 42, 48 and in HFF strains at PDs 26, 30 and 34. These
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Fig. 1 Growth curve and percentage of SA β-Gal positive cells in MRC-5 fibroblasts +/− rotenone treatment. a Growth curve of MRC-5 fibroblasts
supplemented with 0.1 μM rotenone (green) compared to DMSO-treated controls (black). b Percentage of senescence associated SA β-Gal positive
cells in 0.1 μM rotenone-treated young (PD 30) fibroblasts (green), compared to DMSO-treated controls (black). The arrows indicate the time points
at which samples were collected and subjected to next generation sequencing and transcriptome analysis. The bars indicate the mean ± S.D.
Values statistically different from their controls (t-test) are indicated with an asterix: ** p < 0.01, *** p < 0.001. c Percentage of SA β-Gal positive cells
in 0.1 μM rotenone treated mid (PD 52) MRC-5 fibroblasts, compared to untreated controls. n = 3 in all cases
Fig. 2 Growth curve and percentage of SA β-Gal positive cells in human foreskin fibroblasts +/− rotenone treatment. a Growth curve of HFF
fibroblasts supplemented with 0.1 μM rotenone (green), compared to DMSO-treated controls (black). b Percentage of SA β-Gal positive cells in
0.1 μM rotenone treated young HFF fibroblasts (green), compared to DMSO-treated controls (black). The arrows indicate the time points at which
samples were collected and subjected to next generation sequencing and transcriptome analysis. The bars indicate the mean ± S.D. Values
statistically different from their controls (t-test) are indicated with an asterix: * p < 0.05, ** p < 0.01. n = 3 in all cases
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specific PDs were selected due to two criteria: (i) a high
number of DEGs retrieved by RNA-seq (Table 1) and (ii) a
delay in induction of senescence as measured by SA β-Gal
(Figs. 1b and 2b).
In summary, we detected 1113 (568 up- and 545 down-
regulated) rotenone treatment induced DEGs in MRC-5
fibroblasts common for both PDs 42 and 48 (p < 0.05). In
order to identify those genes in this list with the largest
expression difference, we implemented the statistical
stringency criteria (i) p < 0.05, (ii) log2 fold change >1, and
(iii) adherence with both statistical packages (DESeq and
edgeR). 203 DEGs fulfilled these criteria (160 up- and 43
down-regulated). The most significantly up-regulated
genes in this list included Wnt2, CENP-F, IGFBP2 and
ALDH1B1. These four genes had previously been asso-
ciated with proliferation [72–75]. Due to rotenone
treatment significantly down-regulated genes included
Id1, Id3, MMP10, Wnt16 and CTSK which have
previously been demonstrated to be associated with
senescence [76–79]. The significant up-regulation of
IGFBP2, down-regulation of Id1 and Id3 with age and
Table 1 Number of DEGs in primary human fibroblast strains +
/ - rotenone
Fibroblast PD+/− rotenone (R) Number of DEGs
MRC-5 PD38 − R to PD38 + R 1
PD42 − R to PD42 + R 2086
PD48 − R to PD48 + R 3527
PD52 − R to PD52 + R 319
HFF PD22 − R to PD22 + R 1
PD26 − R to PD26 + R 4873
PD30 − R to PD30 + R 8151
PD34 − R to PD34 + R 6424
PD58 − R to PD58 + R 5726
PD74 − R to PD74 + R 60
The number of differentially expressed genes at different population doublings
(PDs) in MRC-5 and HFFs supplemented with low dose (0.1 μM) rotenone
compared to their corresponding controls (without rotenone but with DMSO).
The stringency criteria applied for retrieving the DEGs included p < 0.05 and
alignment with two statistical packages DESeq [68] and edgeR [69]
Fig. 3 Variance and sample clustering of normalized transcriptome expression values. Principal component analysis (PCA) of MRC-5 (spheres) and
HFF (triangles) cell strains of specific PDs (indicated by color) treated with (filled-in symbols) and without (empty symbols) rotenone. The triplicates
are clearly grouped. One of the HFF control sample triplicates of PD34 and PD58 were outliers and were excluded for the analysis, thus only 2
symbols are displayed. The outliers could be attributed to batch effects [116] and their removal from analysis has previously been documented
[117]. Interestingly, samples treated with rotenone at low PDs cluster more likely with low PDs which were not treated. Triplicates (identical
symbols) are clustered indicating small experimental errors. For young (low PDs) and old (high PDs) MRC-5 and HFFs, triplicates with and without
rotenone group together indicating little variance due to rotenone treatment. However, for some intermediate PDs, the triplicates with and
without rotenone differ strongly indicating transcriptome differences due to rotenone treatment
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loss of Id function was observed previously for cells
transiting into senescence [80–82].
The same approach with three statistical stringency
criteria was applied to HFFs. We found a total number of
25 DEGs among the three HFF PDs (18 up- and 7 down-
regulated). Wnt5a and the cyclin dependent kinase inhibi-
tor (CDKI) p21CDKN1A transcript levels were significantly
up-regulated and MMP1 expression levels were signifi-
cantly down-regulated due to 0.1 μM rotenone treatment.
Previous studies had associated Wnt5a with proliferation
[83–85] while the role of p21 in cell cycle arrest and
MMP1 in senescence is well documented [86, 87].
We then determined the most significant DEGs com-
mon among all the above mentioned PDs in both, MRC-5
and HFF, fulfilling the statistical stringency criteria of (i) p
< 0.05 and (ii) adherence with both statistical packages
(DESeq and edgeR) (Additional file 3: Table S2). We
speculated that amongst these genes we could identify
those genes commonly determining the hormetic effect in
both human fibroblast strains. The 12 genes down-
regulated due to low dose rotenone treatment included
MMP3 [86, 88, 89] and CCDC68 while the 18 genes
significantly up-regulated in both fibroblast strains in-
cluded ENPP2 and the Wnt signaling pathway antagonist
SFRP1 (Additional file 3: Table S2). The role of these
genes in senescence has been previously documented [80,
90]. Wnt signaling pathway antagonist SFRP1, an inducer
of cell cycle arrest [90], was significantly up-regulated in
both fibroblasts due to rotenone treatment (see Additional
file 3: Table S2) while not being significantly up-regulated
during aging in either of the fibroblast strains. However,
replicative senescence in HFFs resulted in a significant up-
regulation of SFRP4, a SFRP1 family member [90]. Over-
expression of SFRP4 in young (low PD) HFFs resulted in
pre-mature senescence induction [80]. However, the
observed increase in SFRP1 expression levels due to rote-
none treatment in either of the fibroblast strains did not
result in an increase in the percentage of SA β-Gal stained
cells (Figs. 1b and 2b).
These genes are significantly differentially regulated in
both, MRC-5 and HFF, according to p < 0.05 and adher-
ence to the two statistical packages, however, they did not
fulfill the criteria of log2 fold change >1. Thus, these
common genes were not as significantly differentially reg-
ulated due to rotenone treatment as other genes in the
single cell strains.
We detected a number of genes regulated in opposite
directions when comparing low dose rotenone treatment
with cells transiting into senescence. Up-regulation of
CENP-F and down-regulation of CTSK in MRC-5 in re-
sponse to low dose rotenone was opposite to the differen-
tial regulation of these genes in untreated MRC-5 during
aging [80]. In HFFs, MMP1, a known marker for senes-
cence in fibroblasts [86], was significantly down-regulated
due to rotenone treatment. However, these three genes
are not commonly regulated in both strains (thus not
included in Additional file 3: Table S2). Instead, DEGs
commonly most significantly regulated among all the
above mentioned PDs in both fibroblast strains included
MMP3 and CCDC68, the transcript levels of which were
down-regulated in rotenone treated cells but significantly
up-regulated with age in replicative senescent MRC-5
fibroblasts [80]. ENPP2 was significantly up-regulated
across all the PDs in both the fibroblast cell strains under
mild rotenone stress but significantly down-regulated in
aging HFF, however not in MRC-5 fibroblast strains [80].
Thus, we identified four genes (SFRP1, MMP3, CCDC68
and ENPP2) the expression of which was regulated such
that they are potential candidates for hormesis induction
in MRC-5 and HFFs. However, in each of the two cell
strains, these genes were not the most strongly differen-
tially regulated genes during rotenone treatment, and fur-
thermore, none of the four genes belongs to the pathways
which were most differentially regulated due to low dose
rotenone treatment in either of the cell lines (see below).
In summary, low dose rotenone induced strong differen-
tial regulation of a number of genes in both single cell
strains, however, the change of expression of genes com-
monly differentially regulated in both cell strains, which
would include the potential hormesis regulators, was
weaker. Thus, if there is a common hormesis regulation, it
is superimposed by cell strain specific individual re-
sponses, with the extreme case of WI-38 cells which do
not show hormesis at all.
Rotenone treatment induced differentially expressed
pathways
Using the DAVID functional annotation bioinformatics
tool we then asked whether the genes differentially
regulated on rotenone treatment in either of the fibroblast
strains belonged to any functional category [91]. Genes
significantly (p < 0.05) down-regulated in MRC-5 or HFF
fibroblast strains due to 0.1 μM rotenone treatment were
found to be clustered in a group associated with glycopro-
teins and glycosylation site O-linked N-acetylglucosamine
(GlcNAc). Previous studies revealed a down-regulation of
O-GlcNAc mediated glycosylation activity in association
with bladder inflammation in mice [92].
Next, using Generally Applicable Gene set Enrichment
for pathway analysis (GAGE), we retrieved the KEGG
pathways [71] significantly differentially regulated in the
MRC-5 and HFF fibroblast strains due to 0.1 μM rote-
none treatment (p-value < 0.05).
The pathways significantly (p < 0.05) up-regulated due
to 0.1 μM rotenone treatment in either PD 42 or PD 48
MRC-5 fibroblasts included “DNA replication”, “Cell
cycle”, “Oocyte meiosis”, “RNA transport”, “Adherens
junction”, “Homologous recombination”, “Mismatch
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repair”, “Spliceosome”, “Steroid Biosynthesis”, “Nucleo-
tide excision repair”, “Base excision repair”, “Pyrimidine
metabolism”, “RNA degradation”, “RNA polymerase”
and “Ribosome”. However, only two pathways were
commonly up-regulated in MRC-5 for both PDs: “Fatty
acid metabolism” and “Propanoate metabolism”. Inter-
estingly, these pathways were significantly down-
regulated with age during the transition into senescence
in replicatively aged MRC-5 fibroblasts [80]. Eight path-
ways (“Other glycan degradation”, “Focal adhesion”,
“Regulation of actin cytoskeleton”, “Bacterial invasion
of epithelial cells”, “Endocytosis”, “ErbB signaling”,
“Lysosome” and “Protein processing in endoplasmic
reticulum”) were significantly (p < 0.05) down-regulated
due to rotenone treatment in MRC-5 in at least one of
the two PDs (42 and 48). Interestingly, these pathways
were significantly up-regulated with age during replicative
senescence in MRC-5 fibroblasts [80]. Two pathways,
“Lysosome” and “Protein processing in endoplasmic
reticulum”, were down-regulated at both PDs.
Twenty-five pathways were found up-regulated (p < 0.05)
due to low dose rotenone treatment in HFFs at one of
the PDs 26, 30 or 34 (Additional file 4: Table S3). Among
these, “Ribosome” was the most significantly (p < 0.001)
up-regulated pathway. As observed for MRC-5 cells, these
pathways were down-regulated during replicative HFF
senescence [80]. “Ribosome”, “Chemokine signaling path-
way” and “NOD-like receptor signaling pathway” was
commonly up-regulated in all the three PDs. 30 pathways
were found significantly down-regulated in at least one of
the three PDs (26, 30 and 34) (Additional file 5: Table
S4). The most significantly (p < 0.001) down-regulated
pathways among these 30 included “Lysosome”, “ABC
transporters”, “Drug metabolism-cytochrome P450”, “Me-
tabolism of xenobiotics by cytochrome P450” and “Phago-
some”. Interestingly, these pathways were significantly up-
regulated with age during replicative senescence in HFFs
[80]. Among the 30 pathways, only “Glycosphingolipid
biosynthesis - ganglio series” and “Basal cell carcinoma”
were down-regulated at all 3 PDs in HFFs.
As the next step, we determined those pathways which
were commonly differentially regulated due to rotenone
treatment not only for the relevant PDs of either one cell
strain (see above) but now also for both cell strains, apply-
ing selection criteria of p < 0.05. These either up- or
down-regulated pathways are listed in Additional file 6:
Table S5. A number of pathways, being significantly
down-regulated during transition into senescence [80],
were up-regulated due to low dose rotenone treatment in
both MRC-5 and HFF cell strains (see Additional file 6:
Table S5). These pathways included processes associated
with cell cycle and DNA repair. The rotenone-induced
up-regulation of DNA repair pathways in MRC-5 and
HFF fibroblast strains explains the ability of rotenone to
act against (oxidative) DNA damage. During replicative
senescence, in contrast to rotenone treatment, DNA
repair pathways are down-regulated with age so that
DNA damage accumulates [58, 80]. The up-regulation
of DNA repair genes is consistent with the hormetic ef-
fect of rotenone. In addition, we found mRNA splicing
genes up-regulated due to rotenone in both fibroblast
cell strains (“Spliceosome” pathway). The pathways sig-
nificantly down-regulated in both fibroblast strains due
to rotenone treatment included the “Lysosome” path-
way which was significantly up-regulated with age in
several fibroblast cell strains of different origin [80].
The up-regulation of the “Lysosome” pathway might
reveal the need for degradation of cellular disposals in
aging non-replicating cells [93]. “Phagosome” and
“ABC transporter” pathways were significantly down-
regulated on rotenone treatment in HFF strains while
being significantly up-regulated on replicative aging
[80]. The up-regulation with age of the “Phagosome”
and “ABC transporter” pathways was detected also in
other cell systems [94, 95]. In both fibroblast strains,
the “Ribosome” pathway was significantly up-regulated
due to rotenone treatment and down-regulated during
aging. This pathway was significantly up-regulated dur-
ing brain aging of the short lived fish N. furzeri [96]
and activated on response to ultraviolet B radiation
induced stress [97].
Analyzing the expression levels of the single genes be-
longing to the significantly differentially regulated path-
ways on rotenone treatment in both MRC-5 and HFFs,
resulted in genes which were only differentially regulated
by a log2 fold change <1 compared to untreated controls.
Furthermore, different genes amongst the pathway mem-
bers were responsible for the rotenone induced differential
regulation of a given pathway. For example in MRC-5
fibroblasts, genes PGR and ADH1B belonging to pathways
“Oocyte meiosis” and “Propanoate metabolism” were the
only genes which were up-regulated and Wnt16 belonging
to “Basal cell carcinoma” pathway was the only gene
which was down-regulated with a log2 fold change >1.
Thus, only in these three cases did we observe a differen-
tial up- or down-regulation by log2 fold change >1 com-
pared to controls. All the other genes had a differential
expression of a log2 fold change <1. However, in none of
these cases such a differential regulation was found for
HFF cell strains. The only gene differentially regulated
with a log2 fold change >1 in HFF was CCNB3 belonging
to the “Cell cycle pathway”. In summary, the differential
regulation of the common pathways was weaker than
other pathways identified in the single fibroblast cell
strains, and furthermore, within the common pathways
different genes were responsible for this different regula-
tion. These findings indicate that hormesis induction due
to rotenone treatment is related to a weak pathway signal,
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superimposed by a stronger individual cellular response, a
conclusion as deduced from the DEG results.
We further investigated the expression of genes of the
mTOR pathway, considering them being major regulators
of cell cycle. However, except for DDIT4, belonging to a
group of genes responsible for mTORC1 inhibition, all
other genes of this pathway were not significantly differen-
tially regulated due to rotenone treatment. Low dose rote-
none reduced DDIT4 expression to a significant extent in
both fibroblast strains.
Discussion
Oxidants are important intracellular signaling molecules,
with mROS levels notifying the cell of a changing extracel-
lular environment. Redox-dependent signals induce tran-
scriptional changes in the nucleus leading to cellular
decisions including differentiation, growth, cell death and
senescence [98, 99]. A particular stressor that is incompat-
ible with cell viability might induce larger quantities of
mROS, which non-specifically produce cell damage and
subsequent cell death, while another moderate stressor
might induce smaller quantities of mROS. Relatively
minor damage, induced by intracellular stresses including
metabolic perturbations and genomic instability, increases
ROS levels, predominantly (although not exclusively) from
the mitochondria. Low mROS levels promote adaptation
to the stressor and consequently promote cell survival
[2, 9] since ROS are not simply a chemical inducing
damage but also induce signaling pathways. Thus, the
release of oxidants from the mitochondria, or other
sources, can provoke a secondary protective response
[3, 100]. This phenomenon, termed hormesis (or mito-
hormesis), posits that low ROS levels can induce cellular
defense mechanisms, resulting in health span-promoting
effects, while higher ROS levels can cause cellular and sys-
temic damage, culminating in increased mortality [101].
Thus, ROS production and subsequent induction of ROS
defense can be essential contributors to longevity.
Here, we induced increasing cellular ROS levels by
addition of an external stressor and detected a hormetic
effect in human cell strains. We investigated the effect of a
range of concentrations of rotenone on the growth of
primary human fibroblast strains from different tissue
origin (MRC-5, WI-38 and HFF) maintained in culture in
triplicates. Supplementing with 0.1 μM rotenone revealed
a delay in senescence induction in MRC-5 and HFF (male
from different tissue; Figs. 1b and 2b) but not in WI-38
fibroblast strains (female from same tissue as MRC-5;
Additional file 2: Figure S1B). This rotenone concentra-
tion did not or only to a minor extent affects the cumula-
tive PDs in these three fibroblast strains. To a great
degree, cells are reported to keep their tissue-specific
phenotype in culture [102]. Interestingly, here we found a
similar response for two cell strains (MRC-5 and HFF)
from different tissue but major differences between MRC-
5 and WI-38 strains, both derived from human lung
(though from different genders). A difference between
these two cell strains in response to mild stress had been
observed by us before: an increase in oxygen levels from
3 % to 20 % induced senescence and a shorter life span in
MRC-5 but not in WI-38 cell strains [58], WI-38 cells are
thus less sensitive to higher external oxygen levels. Here,
in response to rotenone treatment, we confirmed the
different properties of these two cell strains. An individual
variation in the hormetic response was also observed in
the resistance to type 2 diabetes mellitus in humans [103].
Concentrations of rotenone higher than 0.1 μM resulted
in apoptosis of the fibroblast strains. Thus, low dose rote-
none induced a hormetic effect [104]. The hormetic effect
was evident however only in young (low PD) but not in
older (higher PDs) cells (Fig. 1c). Possibly, at mid and high
PDs, the amount of ROS in the fibroblasts has already
increased with age to a value above the hormetic level.
The increase of ROS in fibroblasts with age may result in
the impairment of mitochondrial membrane potential
[105]. In addition, MRC-5 fibroblasts at PD 50 already
showed accelerated levels of other typical mediators of
senescence including p16, p21, and γH2AX, while these
markers are not expressed inMRC-5 at PD 30 [58, 106, 107].
Thus, at higher PDs (PD > 50), the senescence-induced
feed-back loop of ROS generation may override any
potential hormetic effect of rotenone [108].
The effect of rotenone treatment has previously been
investigated in other cell lines and experimental model
systems. In MCF-7 cells, 0–20 μM rotenone induced
apoptosis in a dose dependent manner [42], consistent
with our findings. Seven days of treatment with 0.2 μM
rotenone induced senescence in fibroblasts from skin
biopsies derived from healthy humans [36] while, simi-
lar to our results, the higher concentration of 1 μM
after 3 days of treatment resulted in apoptosis [36, 41].
While 0.1 μM rotenone delayed senescence in young
PD MRC-5 fibroblasts in our study, the same concen-
tration resulted in depolarization of the mitochondrial
membrane potential in skin fibroblasts derived from
healthy humans [43]. In muscle derived C2C12 cells,
treatment with 0.005 μM rotenone for 48 h was able to
induce lipotoxicity [35]. However, 0.2 μM and 0.4 μM
rotenone treatment were the highest tolerable concen-
trations for mtDNA mutations in HCT116 cells and
immortalized mouse embryonic fibroblasts, respectively
[44]. In rat skeletal and heart mitochondria, 10 μM
rotenone treatments significantly increased H2O2 pro-
duction [45]. Investigation of rotenone as a stressor in
C. elegans revealed a dose dependent effect on cell sur-
vival. 5 μM rotenone resulted in death of the organism
[46], whereas 0.1 μM rotenone resulted in an extended
lifespan and improved stress resistance in C. elegans
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[40], effects similar to those observed here for MRC-5
and HFF fibroblasts.
Low level rotenone treatment induced an individual
strain specific cellular response. WI-38 cells, found before
to be oxygen insensitive [58], did not show a hormetic ef-
fect at all while, to a considerable extent, MRC-5 and HFF
displayed cell strain specific most differentially expressed
genes and a delayed transition into senescence. By statis-
tical selection we determined the most differentially
expressed genes common for both strains (Additional
file 3: Table S2). Among these, we identified four genes
(SFRP1, MMP3, CCDC68 and ENPP2) with an expression
regulation identifying them as potential candidates for
hormesis induction in fibroblasts. Over- and under ex-
pression of these genes are envisaged to provide experi-
mental proof for this hypothesis.
Several pathways regulated in different directions due to
rotenone treatment compared to transition into senes-
cence were identified. Improved DNA repair capacity and
cell cycle progression could well be underlying mecha-
nisms inducing a hormetic effect after low dose rotenone
treatment. However, on the DEG as well as on the path-
way level, the differential regulation of common genes and
pathways were weak compared to that of others in the
single cell strains. Thus, the rotenone induced common
cellular response is a weak signal, superimposed by indi-
vidual cell-internal gene expression changes. This is con-
sistent with hormesis being a small effect in general, with
the extreme case of WI-38 cells not showing a rotenone
induced hormesis at all. This suggests that the observed
hormetic phenotype does not result from a specific strong
gene or pathway regulation but from weak common
cellular processes, probably induced by low dose ROS
levels [3, 101].
A recent microarray study investigated the effect of
0.6 μM rotenone on fibroblasts from skin biopsies derived
from healthy young (23–25 year old) and aged (90–91
year old) human subjects [109], detecting no significantly
differentially regulated pathways. This higher rotenone
concentration induced apoptosis in the cells studied here.
We observed a hormetic effect only in young (low PD)
fibroblasts.
0.1 μM rotenone supplementation induced a life span
extension in C. elegans [40]. As a consequence of the same
low dose rotenone treatment, we observed a hormetic
effect in two human fibroblast cell strains similar to effects
in C. elegans. We therefore searched for similarities
between the significantly differentially regulated pathways
on rotenone treatment in C. elegans and the fibroblast cell
strains analyzed here. As in our study, rotenone was
supplemented throughout the C. elegans life span. High-
throughput RNA sequencing was conducted at four time
points of the C. elegans life span (after 1, 5, 10 and
20 days), revealing a number of differentially expressed
genes (3460, 158, 2 and 18, respectively) compared to
untreated C. elegans worms. From our comparison, we
excluded the C. elegans rotenone data for day one since
this may be the immediate organismal response to the
addition of a foreign stressor [110, 111]. The compari-
son of the common most differentially regulated path-
ways (p < 0.05) due to 0.1 μM rotenone treatment in C.
elegans and human MRC-5 and HFF fibroblasts revealed
the common up-regulation of ten pathways (“RNA trans-
port”, “Spliceosome”, “DNA replication”, “Nucleotide exci-
sion repair”, “Base excision repair”, “Mismatch repair”,
“Homologous recombination”, “Pyrimidine metabolism”,
“RNA degradation” and “RNA polymerase”). This might
indicate that in both systems low dose rotenone could in-
duce similar mechanisms, resulting in the delay of senes-
cence in fibroblasts and the extension of life span in C.
elegans. However, none of the genes belonging to the
significantly differentially regulated pathways common for
both cell strains and C. elegans had a log2 fold expression
change due to rotenone treatment larger than one in ei-
ther of the two cell strains. Furthermore, analyzing the
genes most differentially expressed due to rotenone
treatment in C. elegans (on days 5 and 10) revealed no
common genes compared to either of the fibroblast
strains; the genes most significantly differentially regulated
in C. elegans have no human orthologues.
Taken together, we find that on the gene and on the
pathway level the dominant cellular response to low level
rotenone is mostly cell strain specific while the observed
common hormetic effect seems to be based on weaker
expression differences. This suggests that hormesis is a
rather individual response, consistent with [103]. Our re-
sults obtained for human fibroblast cell strains show that
hormesis occurs already on the cellular level and not
necessarily requires high-level, like immune or neuronal,
regulatory systems for induction. In animals, immune-
system-related and neuronal hormetic effects are common
[10, 112, 113] and might add to the hormetic effect
induced on the cellular level. Minor stress induced by
rotenone or other hormetic agents activates maintenance
genes (“vitagenes” [10]), including DNA repair genes as
observed here. Our results could be explained by the
hypothesis that minor stress induces an over-shooting
stress-response that does more than necessary, in this way
slightly delaying senescence induction by counteracting
aging effects which are due to the time dependent decay
of cellular systems. The dose dependent response of
hormetic agents has a broad range of biomedical applica-
tions [114]. This observed effect in vitro if translated in
vivo might have an impact on longevity in humans.
Conclusion
In this study, we revealed for the first time a hormetic
effect due to 0.1 μM rotenone in MRC-5 and HFF human
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fibroblast cell strains at early PDs. However, mid and late
PD fibroblasts as well as WI-38 cells lacked this effect.
Only a limited inhibition of complex I was able to induce
hormesis, higher concentrations of rotenone induced
apoptosis in the fibroblast cells. Our data suggest that the
limited inhibition of complex I, inducing low ROS levels,
is beneficial to cell growth while higher levels of complex I
inhibition result in adverse effects by promoting diseases
[115] and affecting life span. Here we found that on the
genes as well as on the pathway level, rotenone induced
cellular hormesis is related to weak signals which are
superimposed by stronger individual cell-internal re-
sponses. This would explain that in general hormesis is a
small effect, with WI-38 cells not showing a rotenone
induced hormesis at all. Our data indicate that the
observed hormetic phenotype does not result from a spe-
cific strong well-defined gene or pathway regulation but
from weak common cellular processes, induced by low
dose ROS levels.
Data deposition
All reads have been deposited in the NCBI GEO under
the accession number GSE64553 and will be made avail-
able at the time of publication.
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